{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:02Z","timestamp":1791357242992,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00228-018-2498-1","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T12:40:04Z","timestamp":1529066404000},"page":"1215-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews"],"prefix":"10.1007","volume":"74","author":[{"given":"Esther Let\u00edcia Amorim","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e1cio","family":"de Mendon\u00e7a Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Eduardo Bergamini","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Storpirtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-4533","authenticated-orcid":false,"given":"Patricia Melo","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"2498_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (APA) (2013) Diagnostic and statistical manual of mental disorders. 5th ed. 2. Mental disorders\u2014classification. 3. Mental disorders\u2014diagnosis","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2498_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12888-015-0578-7","volume":"15","author":"JC Simeone","year":"2015","unstructured":"Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R (2015) An evaluation of variation in published estimates of schizophrenia prevalence from 1990\u20132013: a systematic literature review. BMC Psychiatry 15:193","journal-title":"BMC Psychiatry"},{"issue":"9904","key":"2498_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine H et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden Of Disease Study 2010. Lancet 382(9904):1575\u20131586","journal-title":"Lancet"},{"issue":"suppl 1","key":"2498_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.13049su1c.03","volume":"75","author":"PD Harvey","year":"2014","unstructured":"Harvey PD (2014) Disability in schizophrenia: contributing factors and validated assessments. J Clin Psychiatry 75(suppl 1):15\u201320","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2498_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64(10):1123\u20131131","journal-title":"Arch Gen Psychiatry"},{"key":"2498_CR6","unstructured":"Seida JC, Schouten JR, Mousavi SS, Hamm M, Beaith A, Vandermeer B, et al. (2012) First- and second-generation antipsychotics for children and young adults. Comparative Effectiveness Review No. 39. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290\u20132007-10021.) AHRQ Publication No. 11(12)-EHC077-EF. Rockville: Agency for Healthcare Research and Quality"},{"issue":"5","key":"2498_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7326\/0003-4819-126-5-199703010-00006","volume":"126","author":"DJ Cook","year":"1997","unstructured":"Cook DJ, Mulrow CD, Haynes RB (1997) Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 126(5):376\u2013380","journal-title":"Ann Intern Med"},{"key":"2498_CR8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association (ADA)","year":"2004","unstructured":"American Diabetes Association (ADA) (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596\u2013601","journal-title":"Diabetes Care"},{"key":"2498_CR9","doi-asserted-by":"crossref","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N (2014) Review article second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014:656370","DOI":"10.1155\/2014\/656370"},{"issue":"3\u20134","key":"2498_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jrsm.30","volume":"1","author":"D Thomson","year":"2010","unstructured":"Thomson D, Russell K, Becker L, Klassend T, Hartling L (2010) The evolution of a new publication type: steps and challenges of producing overviews of reviews. Res Synth Methods 1(3\u20134):198\u2013211","journal-title":"Res Synth Methods"},{"key":"2498_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013276","journal-title":"Schizophr Bull"},{"key":"2498_CR12","unstructured":"Sch\u00fcnemann H, Brozek J, Guyatt G, Oxman A, editors (The GRADE Working Group) (2013) GRADE handbook for grading quality of evidence and strength of recommendations. Available from: \n                    http:\/\/www.guidelinedevelopment.org\/handbook\n                    \n                  . Accessed May 12, 2017"},{"issue":"7","key":"2498_CR13","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP (2014) Evaluating the quality of evidence from a network meta-analysis. PLoS One 9(7):e99682","journal-title":"PLoS One"},{"key":"2498_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Savovi\u0107 J, Higgins JP, Caldwell DM, Reeves BC, Shea B, Davies P, Kleijnen J, Churchill R, ROBIS group (2016) ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 69:225\u2013234","journal-title":"J Clin Epidemiol"},{"key":"2498_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.schres.2017.01.002","volume":"185","author":"Z Bai","year":"2017","unstructured":"Bai Z, Wang G, Cai S, Ding X, Liu W, Huang D, Shen W, Zhang J, Chen K, Yang Y, Zhang L, Zhao X, Ouyang Q, Zhao J, Lu H, Hao W (2017) Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis. Schizophr Res 185:73\u201379","journal-title":"Schizophr Res"},{"key":"2498_CR16","doi-asserted-by":"crossref","unstructured":"Belgamwar RB, El-Sayeh HG (2011) Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev (8):CD006622","DOI":"10.1002\/14651858.CD006622.pub2"},{"key":"2498_CR17","doi-asserted-by":"crossref","unstructured":"Bhattacharjee J, El-Sayeh HG (2008) Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (3):CD006617","DOI":"10.1002\/14651858.CD006617.pub3"},{"key":"2498_CR18","doi-asserted-by":"crossref","unstructured":"Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG, et al (2014) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2):CD006569","DOI":"10.1002\/14651858.CD006569.pub5"},{"issue":"6","key":"2498_CR19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/JCP.0b013e31823657d9","volume":"31","author":"M Klemp","year":"2011","unstructured":"Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I (2011) A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol 31(6):698\u2013704","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2498_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bcp.12221","volume":"77","author":"T Kunitomi","year":"2014","unstructured":"Kunitomi T, Hashiguchi M, Mochizuki M (2014) Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia. Br J Clin Pharmacol 77(5):767\u2013776","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2498_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F et al (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166(2):152\u2013163","journal-title":"Am J Psychiatry"},{"issue":"9657","key":"2498_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31\u201341","journal-title":"Lancet"},{"issue":"9896","key":"2498_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951\u2013962","journal-title":"Lancet"},{"key":"2498_CR24","doi-asserted-by":"publisher","unstructured":"Majer IM, Gaughran F, Sapin C, Beillat M, Treur AM (2015) Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. J Mark Access Health Policy 3. doi \n                    https:\/\/doi.org\/10.3402\/jmahp.v3.27208","DOI":"10.3402\/jmahp.v3.27208"},{"issue":"5","key":"2498_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1517\/14740338.2012.712682","volume":"11","author":"H Moteshafi","year":"2012","unstructured":"Moteshafi H, Stip E (2012) Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf 11(5):713\u2013732","journal-title":"Expert Opin Drug Saf"},{"key":"2498_CR26","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.2147\/NDT.S91397","volume":"11","author":"K Oya","year":"2015","unstructured":"Oya K, Kishi T, Iwata N (2015) Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 11:2299\u20132307","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2\u20133","key":"2498_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123(2\u20133):225\u2013233","journal-title":"Schizophr Res"},{"issue":"5","key":"2498_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1570159X13666150115220221","volume":"13","author":"JE Thomas","year":"2015","unstructured":"Thomas JE, Caballero J, Harrington CA (2015) The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol 13(5):681\u2013691","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"2498_CR29","first-page":"120","volume":"29","author":"V Hendrick","year":"2017","unstructured":"Hendrick V, Dasher R, Gitlin M, Parsi M (2017) Minimizing weight gain for patients taking antipsychotic medications: the potential role for early use of metformin. Ann Clin Psychiatry 29(2):120\u2013124","journal-title":"Ann Clin Psychiatry"},{"issue":"suppl. 47","key":"2498_CR30","doi-asserted-by":"publisher","first-page":"s67","DOI":"10.1192\/bjp.184.47.s67","volume":"184","author":"C Bushe","year":"2004","unstructured":"Bushe C, Holt R (2004) Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 184(suppl. 47):s67\u2013s71","journal-title":"Br J Psychiatry"},{"issue":"2","key":"2498_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","volume":"160","author":"MC Ryan","year":"2003","unstructured":"Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160(2):284\u2013289","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2498_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 40(1):195\u2013211","journal-title":"Prim Care"},{"key":"2498_CR33","unstructured":"Joy CB, Adams CE, Lawrie SM (2006) Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev (4):CD003082"},{"key":"2498_CR34","first-page":"23","volume":"455","author":"SD Holder","year":"2017","unstructured":"Holder SD, Edmunds AL, Morgan S (2017) Psychotic and bipolar disorders: antipsychotic drugs. FP Essent 455:23\u201329","journal-title":"FP Essent"},{"issue":"8","key":"2498_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017406","volume":"7","author":"R Sheehan","year":"2017","unstructured":"Sheehan R, Horsfall L, Strydom A, Osborn D, Walters K, Hassiotis A (2017) Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open 7(8):e017406","journal-title":"BMJ Open"},{"issue":"4","key":"2498_CR36","first-page":"e1157","volume":"9","author":"W Nawal","year":"2017","unstructured":"Nawal W, Komal W, Muhammad WS (2017) Bupropion-induced acute dystonia with dose escalation and use of Naranjo nomogram. Cureus 9(4):e1157","journal-title":"Cureus"},{"issue":"6","key":"2498_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/2045125314553970","volume":"4","author":"MS Karthik","year":"2014","unstructured":"Karthik MS, Prabhu N (2014) Temporomandibular joint dislocation due to atypical antipsychotic-induced acute dystonia: a case report. Ther Adv Psychopharmacol 4(6):282\u2013284","journal-title":"Ther Adv Psychopharmacol"},{"key":"2498_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/JPRLS.S99197","volume":"6","author":"PJ Blanchet","year":"2016","unstructured":"Blanchet PJ, Kivenko V (2016) Drug-induced parkinsonism: diagnosis and management. JPRLS 6:83\u201391","journal-title":"JPRLS"},{"issue":"Suppl 2","key":"2498_CR39","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1093\/schbul\/sbr073","volume":"37","author":"S Klingberg","year":"2011","unstructured":"Klingberg S, W\u00f6lwer W, Engel C, Wittorf A, Herrlich J, Meisner C et al (2011) Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull 37(Suppl 2):S98\u2013S110","journal-title":"Schizophr Bull"},{"issue":"13","key":"2498_CR40","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40265-017-0789-y","volume":"77","author":"SRT Veerman","year":"2017","unstructured":"Veerman SRT, Schulte PFJ, Haan L (2017) Treatment for negative symptoms in schizophrenia: a comprehensive review. Drugs 77(13):1423\u20131459","journal-title":"Drugs"},{"key":"2498_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jclinepi.2017.06.019","volume":"91","author":"S B\u00fchn","year":"2017","unstructured":"B\u00fchn S, Mathes T, Prengel P, Wegewitz U, Ostermann T, Robens S, Pieper D (2017) The risk of bias in systematic reviews tool showed fair reliability and good construct validity. J Clin Epidemiol 91:121\u2013128","journal-title":"J Clin Epidemiol"},{"key":"2498_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/jcpe.12893","volume":"45","author":"CM Faggion Jr","year":"2018","unstructured":"Faggion CM Jr, Monje A, Wasiak J (2018) Appraisal of systematic reviews on the management of peri-implant diseases with two methodological tools. J Clin Periodontol 45:754\u2013766. \n                    https:\/\/doi.org\/10.1111\/jcpe.12893","journal-title":"J Clin Periodontol"},{"issue":"10","key":"2498_CR43","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","volume":"62","author":"BJ Shea","year":"2009","unstructured":"Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62(10):1013\u20131020","journal-title":"J Clin Epidemiol"},{"key":"2498_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13643-016-0237-1","volume":"5","author":"BU Burda","year":"2016","unstructured":"Burda BU, Holmer HK, Norris SL (2016) Limitations of A Measurement Tool to Assess Systematic Reviews (AMSTAR) and suggestions for improvement. Syst Rev 5:58","journal-title":"Syst Rev"},{"key":"2498_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12874-015-0062-6","volume":"15","author":"CM Faggion Jr","year":"2015","unstructured":"Faggion CM Jr (2015) Critical appraisal of AMSTAR: challenges, limitations, and potential solutions from the perspective of an assessor. BMC Med Res Methodol 15:63","journal-title":"BMC Med Res Methodol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2498-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2498-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2498-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T19:05:33Z","timestamp":1560539133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2498-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2498-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"25 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no potential conflicts of interest relevant to disclose. The research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}